Spots Global Cancer Trial Database for Phase II Trial of Ontak With Metastatic Melanoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase II Trial of Ontak With Metastatic Melanoma
Official Title: Phase II Trial of ONTAK With Metastatic Melanoma
Study ID: NCT00299689
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to determine whether ONTAK is an effective treatment in patients with Stage IV Melanoma
Detailed Description: This is a Phase II clinical trial to determine whether administration of ONTAK will result in a significant response rate in patients with metastatic melanoma. Although the development of effective immunotherapy and the characterization of multiagent chemotherapy regimens have substantially improved in the treatment of metastatic malignant melanoma, the overall results remain dismal with a 6% five year survival rate for stage IV disease. Of the common adult-onset cancers, melanoma is widely held to be the most amenable to immunological intervention. The primary objective of this study is to determine the response rate and the overall survival of patients with metastatic malignant melanoma treated with two regimens of ONTAK.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
James Graham Brown Cancer Center, Univ. of Louisville, Louisville, Kentucky, United States
Contact Details
Name: Jason Chesney, MD, PhD
Affiliation: University of Louisville
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
